U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H22N2S.C4H6O6
Molecular Weight 436.522
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THENALIDINE TARTRATE

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCC(CC1)N(CC2=CC=CS2)C3=CC=CC=C3

InChI

InChIKey=JNZAGODMPIMPAM-LREBCSMRSA-N
InChI=1S/C17H22N2S.C4H6O6/c1-18-11-9-16(10-12-18)19(14-17-8-5-13-20-17)15-6-3-2-4-7-15;5-1(3(7)8)2(6)4(9)10/h2-8,13,16H,9-12,14H2,1H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1

HIDE SMILES / InChI

Molecular Formula C17H22N2S
Molecular Weight 286.435
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.drugbank.ca/drugs/DB04826 http://www.un.org/esa/coordination/CL12.pdf

Thenalidine is an antihistamine with anticholinergic properties used as an antipruritic drug. It was withdrawn from the US, Canadian, and UK markets due to a risk of neutropenia. Thenalidine is an antagonist of the H1-receptor.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Sandostene

Approved Use

for the management of dermatologic and allergic conditions

Launch Date

1952
Doses

Doses

DosePopulationAdverse events​
25 mg 3 times / day multiple, oral (starting)
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Agranulocytosis...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis (grade 5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Agranulocytosis grade 5
Disc. AE
25 mg 3 times / day multiple, oral (starting)
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
The effect of antihistaminics on cataleptogenic action of analgesics and haloperidol.
1983
Patents

Sample Use Guides

Thenalidine was given in coated tablets, each containing 25 mg. of the active ingredient. The initial dosage was 2 tablets 4 times a day until the patient improved, or for at least one week. The maintenance dose varied between 3 and 6 tablets daily, 4 tablets daily being the average. Intravenous injection of 10 ml. of thenalidine tartrate plus calcium (50 mg. of Sandostene and 1.375 g. of calcium gluconogalactogluconate) was given in a few severe and acute cases only.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:59:11 GMT 2023
Edited
by admin
on Fri Dec 15 17:59:11 GMT 2023
Record UNII
H581Q95SJA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THENALIDINE TARTRATE
MART.   WHO-DD  
Common Name English
1-METHYL-4-AMINO-N-PHENYL-N-(2-THENYL)PIPERIDINE TARTRATE
Common Name English
SANDOSTEN
Brand Name English
SANDOSTENE
Brand Name English
THENALIDINE TARTRATE [MART.]
Common Name English
SANDOSTEIN
Brand Name English
THENOPHENOPIPERIDINE TARTRATE
Common Name English
Thenalidine tartrate [WHO-DD]
Common Name English
4-PIPERIDINAMINE, 1-METHYL-N-PHENYL-N-(2-THIENYLMETHYL)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (1:1)
Systematic Name English
AS-716
Code English
Code System Code Type Description
CAS
16509-35-6
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
SUPERSEDED
EPA CompTox
DTXSID90937038
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
EVMPD
SUB04771MIG
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
PUBCHEM
27900
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
FDA UNII
H581Q95SJA
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
ECHA (EC/EINECS)
220-493-8
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
SMS_ID
100000084801
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
CAS
2784-55-6
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY